- Home
- RVT vs SDGR Comparison
RVT vs SDGR Comparison
Compare RVT & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVT
- SDGR
- Stock Information
- Founded
- RVT 1986
- SDGR 1990
- Country
- RVT United States
- SDGR United States
- Employees
- RVT N/A
- SDGR 787
- Industry
- RVT Trusts Except Educational Religious and Charitable
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- RVT Finance
- SDGR Health Care
- Exchange
- RVT Nasdaq
- SDGR Nasdaq
- Market Cap
- RVT 1.9B
- SDGR 1.5B
- IPO Year
- RVT N/A
- SDGR 2020
- Fundamental
- Price
- RVT $14.96
- SDGR $20.56
- Analyst Decision
- RVT
- SDGR Buy
- Analyst Count
- RVT 0
- SDGR 5
- Target Price
- RVT N/A
- SDGR $32.80
- AVG Volume (30 Days)
- RVT 243.4K
- SDGR 1.1M
- Earning Date
- RVT 01-01-0001
- SDGR 07-30-2025
- Dividend Yield
- RVT 7.32%
- SDGR N/A
- EPS Growth
- RVT N/A
- SDGR N/A
- EPS
- RVT 2.95
- SDGR N/A
- Revenue
- RVT N/A
- SDGR $230,492,000.00
- Revenue This Year
- RVT N/A
- SDGR $24.44
- Revenue Next Year
- RVT N/A
- SDGR $22.17
- P/E Ratio
- RVT $4.98
- SDGR N/A
- Revenue Growth
- RVT N/A
- SDGR 22.29
- 52 Week Low
- RVT $11.85
- SDGR $16.60
- 52 Week High
- RVT $14.93
- SDGR $28.47
- Technical
- Relative Strength Index (RSI)
- RVT 55.80
- SDGR 38.35
- Support Level
- RVT $14.41
- SDGR $20.04
- Resistance Level
- RVT $14.90
- SDGR $20.88
- Average True Range (ATR)
- RVT 0.22
- SDGR 1.24
- MACD
- RVT -0.02
- SDGR -0.28
- Stochastic Oscillator
- RVT 64.61
- SDGR 9.51
About RVT Royce Value Trust Inc.
Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.